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Abstract: Chronic regional pain syndrome (CRPS) can be intractable to treat and patients 
sometimes suffer for many years. Therefore, new treatment strategies are needed to alleviate 
symptoms in CRPS patients. This case report describes a patient suffering from intractable CRPS 
type 1 for 13 years. Due to her swollen painful feet and left knee she is wheelchair-bound. The 
combination of palmitoylethanolamide and ketamine 10% cream reduced her pain by more than 
50% after 1 month of treatment, and a marked reduction in swelling and skin discoloration was 
noticed. Furthermore, she could walk independently again and she experienced no side effects. 
Thus, palmitoylethanolamide and topical ketamine could be a combination therapy option for 
treating CRPS patients.
Keywords: palmitoylethanolamide, ketamine, cream, CRPS, endocannabinoid, sudeck, 
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Introduction
The etiology and pathogenesis of chronic regional pain syndrome (CRPS) is poorly 
understood and the syndrome is often misdiagnosed and undertreated. There is usually 
a delay of many months between the onset of symptoms and the clinical diagnosis 
of CRPS.1 To date, there is no consensus on how to treat CRPS type 1 and type 2. 
Many patients suffering from these disorders remain in pain and have to live with 
a functional handicap. Most patients who do not respond to initial interventions are 
treated with a multitude of analgesics, such as pregabaline, gabapentine, tramadol, 
and/or amitriptyline. However, proof from well-powered, double-blind, placebo-
controlled clinical trials for the efficacy of these analgesics in CRPS is lacking. Most 
clinical trials in this field are small and have short follow-up periods.2
While analgesics may occasionally decrease pain, very often increasing dosages 
are not well tolerated and patients refrain from treatment. Bisphosphonates and radical 
scavengers, such as topical dimethyl sulfoxide (DMSO) 50% cream, might also bring 
relief.3 However, there is clearly an urgent need for new innovative approaches that 
are not only effective, but also have a favorable profile in terms of side effects and 
drug interactions. In particular, multimodal treatment strategies for complex pain 
syndromes, such as neuropathic pain and CRPS, are needed to effectively alleviate 
symptoms.4 At the 14th World Congress on Pain 2012, the importance of multimodal 
therapy was again outlined, and, specifically related to our topic, the authors pointed 
out that “a further approach to treating neuropathic pain is to harness endogenous 
regulatory mechanisms that suppress excessive inflammation.”5
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Palmitoylethanolamide (PEA) harnesses the endogenous 
regulatory mechanisms suppressing chronic neurogenic 
inflammation, and can be well combined with topical 
compounded analgesic creams. In the case described below, 
PEA is combined with ketamine 10% cream, which has a 
documented antiallodynic action. We will present a case of 
severe chronic intractable CRPS type 1 that responded well 
to this treatment regime. We will focus on the therapeutic 
role of PEA. The details related to compounded analgesic 
creams and their effect in CRPS and neuropathic pain are 
presented in more detail elsewhere.6–9
Case
A 72-year-old woman with intractable CRPS type 1 severe 
pain for 13 years. The syndrome developed after she fell on 
the stairs and bruised her ankle. An X-ray did not show any 
fracture. Initially, pain, swelling, and a subjective feeling of 
severe heat developed in her left foot. Resting with the feet 
up and cooling with cool packs reduced some of the pain and 
heat sensation. After several months, however, the symptoms 
spread to her right foot. Both feet were swollen, the skin felt 
very hot and was shiny, the color was red and bluish, and all 
toenails were dystrophic. The diagnosis of CRPS at that time 
was already made by the general practitioner. After 2 years, 
this patient was referred to a specialized clinic for a second 
opinion, due to the fact that the symptoms had worsened. 
Medical examination revealed swelling and hypertrophy 
of the skin; putting the feet down aggravated the pain and 
increased the abnormal skin color.
All symptoms at that time reconfirmed the diagnosis 
CRPS type 1 according to the Veldman criteria: temperature 
differences, edema, color change, and increasing pain upon 
movement.10
The severe burning pain made sleeping difficult and the 
patient had to cool her feet during the night. The bed sheets 
caused allodynia. She had very severe peaks of pain, and 
her average pain score was 6–8 on the 11 point numerical 
rating scale (NRS), in which 0 is no pain and 10 the most 
severe pain imaginable. Her quality of life was poor and she 
scored 4 on the NRS in which 0 is terrible and 10 excellent.
During the 13 years of her CRPS, the patient had 
been treated with various treatments and painkillers by 
anesthesiologists and neurologists, such as physiotherapy, 
amitriptyline 25 mg ante noctum, N-acetylcysteine 800 mg, 
and chlorothalidone 25 mg. Vasodilatating drugs and alcohol 
had produced counterproductive effects, leading to an increase 
of pain and swelling. DMSO 50% cream applied locally on the 
feet also did not alleviate her symptoms. Only amitriptyline 
had some positive effects, but these effects were limited due to 
the fact that higher dosages were badly tolerated.
Due to the severe allodynia in both feet, the patient hardly 
walked anymore, but still rode her bicycle. Mid-2012, while 
biking, she unfortunately hit an obstacle, fell off the bike, 
and hurt her left knee.
The CRPS surged due to the fall and spread from the 
left foot to the knee. In November 2012, when she came to 
our Institute for Neuropathic Pain, the left knee, as well as 
both feet, were profoundly swollen and the skin was red and 
bluish (Figure 1). The patient experienced severe impairment 
of functioning: walking was almost impossible and toe and 
foot extensions were impaired. Thus, the patient presented 
herself as a severe, generalized, intractable CRPS type 1.
The patient’s pain was 6 to 8 on the NRS and her quality 
of life was poor at the first visit in November 2012. She was 
wheelchair bound due to the severe pain, and had swollen 
feet and left knee. The patient reported her general feelings 
as very bad and described her life as being a burden.
As all usual treatment methods had been previously 
attempted, we started treating with our combined treatment 
strategy for CRPS: ketamine 10% cream was applied locally 
three times daily and PEA, as PeaPure® 400 mg capsules 
(JP Russell Sciences Ltd, Nicosia, Cyprus), was taken orally 
three times daily. The instruction for PEA administration was 
to open the capsules and pour the contents under the tongue for 
the first 10 days, and then PEA was to be taken orally. This 
administration was suggested in order to avoid the first pass 
effect and thus heighten the bioavailability of the substance, 
which might lead to a more robust and faster effect. Formal 
bioavailability studies supporting our administration, however, 
are not known. After 10 days, the patient returned to our institute 
walking, albeit with a cane. The swelling, discoloration, and 
pain in her feet were remarkably reduced. One month later her 
symptoms were alleviated even more and pain was reduced 
by more than 50%. An interview with her at this time point 
Figure 1 Chronic regional pain syndrome in the patient’s feet. (A) Before treatment. 
(B) After treatment with 10% ketamine cream and palmitoylethanolamide.
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is documented on video (see Video S1 in “Supplementary 
material”).
After 1 month of treatment, the swelling and discolor-
ation improved even further (Figure 1). The patient no longer 
required a cane for walking; such a decrease in her invalidity 
had never occurred in the previous 13 years. Two months later, 
improvement of her clinical condition continued.
Dose regime of PEA and ketamine 
10% cream in CRPS
As described above, one of our strategies is to treat refractory 
neuropathic and CRPS pain with a combination of PEA 
(PeaPure®,1200 mg daily; JP Russell Sciences Ltd) and topical 
compounded racemic ketamine 10% cream. The rationale for 
prescribing topical ketamine is based on its affinity for the 
N-methyl-D-aspartate receptors, which are present both in the 
central nervous system and also peripherally.11 Also, allodynia 
seems particularly responsive to ketamine cream.12
Our advice for the ketamine 10% cream is to apply 
1–2 gram on the painful area, maximally three to four times 
daily. To date, systemic side effects have not been reported 
in our institute. We then recommend that a lesser amount of 
cream be applied.
Regarding PEA, we start dosing three times daily with 
400 mg, and in the case of severe pain syndromes we 
recommend that for the first 10 days the PEA powder is to 
be sprinkled from the capsule sublingually to reduce the 
first-pass effect. PEA powder is tasteless and melts under the 
tongue within minutes, without producing much saliva, thus 
has superior characteristics over other PEA products, which 
are usually sweetened with sorbitol. After 4 weeks, in case of 
a partial response (defined as less than 30% pain reduction 
compared to baseline), we increase the dose to two capsules 
of 400 mg twice daily (1600 mg PEA daily), to be, based on 
symptoms and the judgment of the physician, increased even 
further up to 2000 mg PEA daily. The dose–response curve 
based on different pharmacological models is 10–30 mg/kg 
body weight. For a person of 70 kg this would translate to 
around 2000 mg PEA daily. If pain is reduced by at least 50%, 
we do not increase the dose further, but stay with 1200 mg 
PEA daily for at least 6 weeks. During that period of time, 
we evaluate whether the pain reduction is stable, and, if so, 
under the PEA regime, we start tapering out conventional 
analgesics. This is also quite often by request of the patient, 
as the conventional analgesics usually impair daily activities 
due to their side effects.
If pain reduction is stable even after slowly tapering out 
various coanalgesics, we keep the patient stable for another 
period of 1 month before exploring lower doses of PEA, 
tapering to 400 mg, twice daily. We again check stability 
and, after one more month, we allow patients to reduce their 
dose to 400 mg a day. In case of increasing pain or signs 
of inflammation we increase the dose again accordingly. If 
symptoms remain absent after another month at 400 mg a 
day, PEA treatment can be stopped.
The role of nonneuronal cells in CRPS
Research on the effects of nonneuronal cells in the 
pathogenesis of CRPS is scarce, and more is known 
about the role of these cells in neuropathic pain. CRPS is, 
however, sometimes regarded as a type of neuropathic pain 
and carries some of the same characteristics.13 CRPS might 
also be associated with an autoantibody-mediated process, 
including alterations in central and peripheral inflammatory 
pathways.14,15
Nonneuronal cells, such as glial and mast cells, play a key 
role in the pathogenesis of CRPS, and one research group even 
introduced the term “gliopathic pain” for neuropathic pain.16 
Mast cells have been recognized as playing a causative role 
in the development of hyperalgesia following nerve injury, 
and their pathogenic involvement has also been demonstrated 
in a great variety of pain syndromes, such as chronic low-
back pain, visceral pain, and CRPS.17 Moreover, mast cell 
degranulation activates central pain pathways and elicits 
behavioral pain hypersensitivity.18 Glial cells and, especially, 
microglia, which are known to functionally interact with mast 
cells, contribute to central and peripheral sensitization.19 In 
addition, animal models of CRPS support the role of mast 
cells in the pathogenesis of CRPS after trauma.20–22
In a specific rat model for CRPS, which involved 
immobilizing the hindpaw after fracturing, mechanical 
allodynia developed hand in hand with chronic upregulated 
tumor necrosis factor (TNF)-α expression in the hindpaw skin 
and the sciatic nerve, as well as increased cFos in the spinal 
medulla.21 Soluble TNF-α receptor type 1 could reverse all 
of these readouts and blocking TNF-α in a clinical setting 
also resulted in positive effects in CRPS.23
In the same model, the relevance of mast cells in the 
pathogenesis of CRPS was shown.22 These preclinical findings 
are in line with clinical findings, where biomarkers indicative 
for inflammation as well as for mast-cell hyperactivation have 
been described in CRPS patients.24–26
PEA
The therapeutic efficacy of PEA has been tested in a multitude 
of indications related to inflammation and pain, and, in both 
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animal models and clinical trials, PEA has proven to be safe 
and effective.27–35 This compound might become a promising 
new therapeutic possibility for CRPS, especially considering 
that its targets are nonneuronal cells: the mast cell and the 
glia cell.19,36 Both nonneuronal cells have been recognized 
since the last decade as important contributors to neuropathic 
pain and neuroinflammation.
PEA is a naturally occurring fatty acid amide, belonging 
to the class of the nuclear factor peroxisome proliferator-
activated receptor (PPAR)-α agonists. In addition to its 
affinity for the PPAR-α, it has high affinity for the GPR55 
receptor.37 PEA and related acylethanolamides are also 
involved in other mechanisms of action, such as influencing 
TRPV1, inhibiting nitric oxide, and enabling an entourage 
effect via anandamide and/or via influencing membrane lipid 
fluidity via lipid rafts.38–49
Previously, PEA was characterized as an endocannabinoid, 
but PEA has no affinity for cannabinoid receptors 1 or 2.50,51 
Amide lipids such as PEA are widely present in nature, in a 
variety of plant, invertebrate, and mammalian tissues.52 PEA 
is also present in many food products, such as peanuts, egg 
yolk, and soy beans.53
PEA is available for the treatment of chronic pain and 
chronic inflammation under the trade names Normast and 
PeaPure. Normast (Epitech Group, Padua, Italy) is formulated 
as matrix tablets and as powder for sublingual use in sachets. 
PeaPure is formulated as powder in vegetable capsules. 
There are some pharmaceutical differences between both 
formulations. For instance, Normast compressed tablets 
contain 600 mg micronized PEA in a magnesium stearate 
matrix; Normast sachets contain 600 mg micronized PEA that 
is sweetened with 300 mg sorbitol. PeaPure is a formulation 
in vegetable capsules containing 400 mg micronized PEA 
only, without any excipients or sweeteners.
PEA first attracted attention in 1957, with its isolation 
from soybeans, peanuts, and egg yolk and the identification of 
its antiinflammatory activity.53 PEA is produced in the body on 
demand and accumulates locally during several inflammatory 
and pain disorders, eg, intestinal inflammation,54 neuropathic 
pain,55,56 cerebral ischemia,57 and multiple sclerosis.58 The 
antiinflammatory and antihyperalgesic activity of PEA 
suggests that this molecule is an endogenous regulator of 
nociception and inflammation.59 To date, there are more 
than 330 papers pertaining to PEA in the medline database, 
covering both clinical as well as preclinical studies.
In the 1990s, the relationship between anandamide and 
PEA was first described, with growing insight into their 
capacity to modulate pain sensitivity and inflammation.60 
In the course of these studies, it emerged that PEA could 
alleviate, in a dose-dependent manner, pain behaviors 
elicited in mouse pain models and downregulate mast-cell 
hyperactivity.61,62
Mast cells, as immunomodulary cells, are often found in 
proximity to sensory nerve endings. Their degranulation (ie, 
the release of many different bioactive mediators stored in 
intracellular granules) can enhance the nociceptive signal, 
which is why peripheral mast cells are considered to be both 
proinflammatory and pronociceptive.63 For example, mast 
cells synthesize, store, and release nerve growth factor,64 
which itself produces inflammation and sensitization of 
the peripheral terminals of sensory neurons.65 Mast cells 
are also found in the spinal dura, the thalamus, and the 
dura mater.63,66 The release of a vast array of mediators 
may well account for the mast cell’s broad involvement 
in physiological and pathophysiological functions and 
diseases. Mast-cell modulation by PEA might thus be 
relevant for disorders in which mast cells are involved, 
such as pelvic pain, sciatic pain, headache, postsurgical 
pain, and CRPS. Studies have demonstrated that PEA can 
downregulate mast cells in vitro and in vivo, resulting in 
decreased release of various inflammatory mediators such 
as histamine, TNF-α, prostaglandins, nerve growth factor, 
and serotonin.67–69
Combination of PEA with analgesics, such as tramadol, 
pregabalin, gabapentin, amitriptyline, and duloxetine, has not 
thus far been reported to create adverse interactions.17
The only side effects of PEA we have seen were related 
to a feeling of heaviness in the stomach after the matrix 
tablets were taken and, rarely, gastrointestinal discomfort and 
diarrhea after the sublingual PEA formulation, probably due 
to the presence of sorbitol as a sweetener. For PeaPure, we 
have not yet registered any side effects, probably due to the 
absence of pharmaceutical excipients and sorbitol.
Conclusion
The case described herein illustrates the positive effects of 
treatment of CRPS with a combination of PEA and topical 
ketamine 10% cream, without any side effects. In complex 
chronic pain cases, such as CRPS, monotherapy usually 
does not give the desired results. Therefore, multimodal 
therapies such as PEA together with ketamine 10% cream 
can be considered a potentially promising therapy in CRPS 
patients with good tolerability.
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Supplementary material
Video S1
Chronic regional pain syndrome for 13 years treated with 
natural palmitoylethanolamide. Available from: http://www.
youtube.com/watch?v=eHEPlszfo30.
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